BioSense exercises option for Chinese rights to Neovacs's IFNalpha Kinoid to treat lupus

BioSense Global LLC (East Rutherford, N.J.) exercised its option under a 2017 deal to acquire exclusive rights from Neovacs S.A. (Euronext:ALNEV) to develop and commercialize IFNalpha-Kinoid to treat lupus, in China. Neovacs will receive an undisclosed milestone payment for the exercised option. The company is eligible for up to €65 million ($75.2 million) in upfront and in milestone payments, plus double-digit royalties.

Neovacs said BioSense exercised the option following results from a Phase IIb trial of IFNalpha-Kinoid, an immunotherapy against interferon (IFN) α...